Vanguard Group Inc. Buys 77,451 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Vanguard Group Inc. lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 1.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,440,005 shares of the medical device company’s stock after purchasing an additional 77,451 shares during the quarter. Vanguard Group Inc. owned about 11.33% of Tandem Diabetes Care worth $267,989,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. AlphaQuest LLC raised its stake in Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after buying an additional 541 shares during the period. Jones Financial Companies Lllp raised its position in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after purchasing an additional 748 shares during the period. Assetmark Inc. lifted its holdings in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock worth $44,000 after purchasing an additional 535 shares in the last quarter. McIlrath & Eck LLC acquired a new stake in Tandem Diabetes Care in the 3rd quarter valued at $52,000. Finally, Smartleaf Asset Management LLC increased its stake in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 1,101 shares in the last quarter.

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction dated Friday, March 7th. The shares were bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Robert W. Baird cut their price target on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Royal Bank of Canada lowered their price objective on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Barclays decreased their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Finally, The Goldman Sachs Group dropped their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average price target of $45.38.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock opened at $16.88 on Friday. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The business’s 50 day simple moving average is $26.36 and its 200 day simple moving average is $32.24. Tandem Diabetes Care, Inc. has a 12 month low of $16.08 and a 12 month high of $53.69. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -8.75 and a beta of 1.45.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.